A color card depicting how results of a mutation profile in patients with MF might be used to make decisions about ruxolitinib (Ruxo) therapy at baseline and during treatment. JAK2VF >50%, presence of JAK2V617F mutation with an allelic burden >50%; HMR⁺, presence of high-molecular-risk mutations (ASXL1, EZH2, SRSF2, IDH1, IDH2); SCT, stem cell transplantation.